Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

FDA Approval of a new dosing regimen for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)

November 21, 2022 11:37 AM | Katy Monaco (Administrator)

FDA approved a new Monday-Wednesday-Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze, Jazz Pharmaceuticals). Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings, and 50 mg/m2 intramuscularly on Friday afternoon. It also is approved to be administered every 48 hours at a dose of 25 mg/m2 intramuscularly.  Read More.


ADDRESS

860 Winter Street, Waltham, MA, 02451

CONTACT US

tel: 781.434.7329

msco@mms.org

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software